승인 제네릭 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global authorized generics market size is expected to reach USD 15.26 Billion in 2034 from USD 8.42 Billion in 2025, growing at a CAGR of 6.83 during 2026-2034.This market is experiencing healthy expansion as healthcare systems increasingly prioritize affordable medicines while maintaining high standards of quality and therapeutic equivalence. Authorized generics provide patients with lower-cost alternatives manufactured under the original branded drug authorization, supporting broader treatment accessibility. Growing demand for cost-effective pharmaceutical products and increasing pressure to reduce healthcare expenditure are strengthening industry growth worldwide.

Patent expirations, expanding generic substitution policies, and favorable regulatory frameworks are major drivers supporting market development. Pharmaceutical companies are utilizing authorized generics to extend product life cycles while maintaining competitive market presence. Rising healthcare awareness, improved medicine accessibility, and increasing demand from public healthcare programs continue creating favorable conditions for sustained industry expansion across multiple therapeutic categories.

Future growth is expected to accelerate as governments promote affordable healthcare and encourage greater adoption of generic medicines. Increasing competition among pharmaceutical manufacturers will stimulate innovation in manufacturing efficiency and supply chain optimization. Continued patent expirations, healthcare reforms, and expanding pharmaceutical access initiatives are anticipated to create significant long-term opportunities for the authorized generics industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Area

• Cardiovascular
• CNS
• Anti-infectives
• Oncology & Supportive Care
• Endocrine & Metabolic
• Respiratory
• Others

By Route of Administration

• Oral
• Parenteral
• Topical
• Inhalation
• Others

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

COMPANIES PROFILED

• Amneal Pharmaceuticals Inc., GSK plc, Hikma Pharmaceuticals PLC, Lupin Limited, Padagis LLC, Pfizer Inc., Prasco LLC, Sandoz AG, Teva Pharmaceutical Industries Ltd., Viatris Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AUTHORIZED GENERICS MARKET: BY THERAPY AREA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Area
• 4.2. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. CNS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Anti-infectives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Oncology & Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Endocrine & Metabolic Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Respiratory Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AUTHORIZED GENERICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Inhalation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AUTHORIZED GENERICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AUTHORIZED GENERICS MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Therapy Area
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Therapy Area
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Therapy Area
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Therapy Area
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Therapy Area
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AUTHORIZED GENERICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Amneal Pharmaceuticals Inc
  • 9.2.2 GSK Plc
  • 9.2.3 Hikma Pharmaceuticals PLC
  • 9.2.4 Lupin Limited
  • 9.2.5 Padagis LLC
  • 9.2.6 Pfizer Inc
  • 9.2.7 Prasco LLC
  • 9.2.8 Sandoz AG
  • 9.2.9 Teva Pharmaceutical Industries Ltd
  • 9.2.10 Viatris Inc